Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]MODAG-009
- Development stage
- Phase 1
- Lead developer
- Modag
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[18F]MODAG-009 is a fluorine-18 labeled positron emission tomography (PET) radiotracer developed by MODAG GmbH for the non-invasive imaging of alpha-synuclein (α-syn) aggregates in the brain. Alpha-synuclein misfolding and aggregation are the pathological hallmarks of synucleinopathies, a group of neurodegenerative disorders that includes Parkinson's disease (PD), Multiple System Atrophy (MSA), and Dementia with Lewy Bodies (DLB). As a diagnostic imaging agent, [18F]MODAG-009 is designed to cross the blood-brain barrier and bind with high affinity and selectivity to α-syn deposits, enabling the quantification and visualization of protein pathology in living patients. This capability is intended to support early and accurate diagnosis, patient stratification in clinical trials, and the monitoring of disease progression or therapeutic response to α-syn-targeting treatments.
- Other names
- [18F]MODAG-009 PET Radiotracer
02
Targets
aggregated α-syn (Alpha-synuclein (α-syn))
Beyond the preview
Go deeper on [18F]MODAG-009.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [18F]MODAG-009.